Analysts Set Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Price Target at $15.65

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has received a consensus recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $17.75.

Several equities research analysts recently issued reports on AUPH shares. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Tuesday, July 16th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Aurinia Pharmaceuticals in a report on Tuesday, June 4th. Finally, BidaskClub downgraded Zynerba Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 29th.

Institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in Aurinia Pharmaceuticals by 7.9% in the fourth quarter. FMR LLC now owns 5,049,740 shares of the biotechnology company’s stock worth $34,439,000 after purchasing an additional 368,781 shares during the last quarter. NEA Management Company LLC boosted its position in Aurinia Pharmaceuticals by 7.6% in the first quarter. NEA Management Company LLC now owns 5,172,683 shares of the biotechnology company’s stock worth $33,622,000 after purchasing an additional 364,200 shares during the last quarter. Redmile Group LLC purchased a new position in Aurinia Pharmaceuticals in the first quarter worth $2,101,000. D. E. Shaw & Co. Inc. boosted its position in Aurinia Pharmaceuticals by 47.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 388,811 shares of the biotechnology company’s stock worth $2,652,000 after purchasing an additional 124,940 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in Aurinia Pharmaceuticals by 413.2% in the fourth quarter. Deutsche Bank AG now owns 66,200 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 53,300 shares during the last quarter. Institutional investors and hedge funds own 32.54% of the company’s stock.

Aurinia Pharmaceuticals stock traded down $0.04 during trading on Tuesday, hitting $6.30. 204,078 shares of the company were exchanged, compared to its average volume of 402,912. The firm has a 50 day simple moving average of $6.37. Aurinia Pharmaceuticals has a 52 week low of $5.06 and a 52 week high of $7.85. The company has a market capitalization of $577.37 million, a P/E ratio of -8.29 and a beta of 1.09.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). Aurinia Pharmaceuticals had a negative return on equity of 48.36% and a negative net margin of 8,435.08%. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. On average, research analysts predict that Aurinia Pharmaceuticals will post -0.65 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Recommended Story: Blue-Chip Stocks

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.